Ashley Bruns

402 total citations
11 papers, 173 citations indexed

About

Ashley Bruns is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ashley Bruns has authored 11 papers receiving a total of 173 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ashley Bruns's work include PARP inhibition in cancer therapy (3 papers), Cancer therapeutics and mechanisms (2 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Ashley Bruns is often cited by papers focused on PARP inhibition in cancer therapy (3 papers), Cancer therapeutics and mechanisms (2 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Ashley Bruns collaborates with scholars based in United States. Ashley Bruns's co-authors include Charles G. Drake, Avery Spitz, Hao Wang, Channing J. Paller, Samuel R. Denmeade, Victoria J. Sinibaldi, Mario A. Eisenberger, Michael T. Schweizer, Michael A. Carducci and Jun Luo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Ashley Bruns

9 papers receiving 170 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ashley Bruns United States	4	120	80	60	45	35	11	173
David T. Hoang United States	5	113 0.9×	114 1.4×	76 1.3×	47 1.0×	64 1.8×	7	256
Lori Kollath United States	5	140 1.2×	126 1.6×	76 1.3×	9 0.2×	60 1.7×	7	234
Maria D. Fenor de la Maza United Kingdom	7	85 0.7×	53 0.7×	56 0.9×	9 0.2×	32 0.9×	17	152
S Whitney United States	4	215 1.8×	149 1.9×	72 1.2×	50 1.1×	77 2.2×	5	307
Delila Gasi Tandefelt Netherlands	7	162 1.4×	125 1.6×	29 0.5×	11 0.2×	105 3.0×	11	233
Cathleen Nientiedt Germany	7	122 1.0×	65 0.8×	75 1.3×	12 0.3×	24 0.7×	12	177
John Shou United States	4	190 1.6×	229 2.9×	52 0.9×	24 0.5×	115 3.3×	8	348
Owais Nadeem United States	2	201 1.7×	118 1.5×	19 0.3×	13 0.3×	77 2.2×	5	228
Natalja Eigėlienė Finland	9	74 0.6×	45 0.6×	67 1.1×	8 0.2×	82 2.3×	12	153

Countries citing papers authored by Ashley Bruns

Since Specialization

Citations

This map shows the geographic impact of Ashley Bruns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashley Bruns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashley Bruns more than expected).

Fields of papers citing papers by Ashley Bruns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashley Bruns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashley Bruns. The network helps show where Ashley Bruns may publish in the future.

Co-authorship network of co-authors of Ashley Bruns

This figure shows the co-authorship network connecting the top 25 collaborators of Ashley Bruns. A scholar is included among the top collaborators of Ashley Bruns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashley Bruns. Ashley Bruns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Coyne, Geraldine O’Sullivan, T. Khanh, Shivaani Kummar, et al.. (2025). Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors. JCO Precision Oncology. 9(9). e2500055–e2500055.

Shin, Sarah J., Geraldine O’Sullivan Coyne, Howard Streicher, et al.. (2022). Abstract CT147: Phase 1 study of recombinant interleukin 15 (rhIL-15) in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers. Cancer Research. 82(12_Supplement). CT147–CT147. 1 indexed citations

Coyne, Geraldine O’Sullivan, Naoko Takebe, Abdul Rafeh Naqash, et al.. (2021). Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 3088–3088. 3 indexed citations

Naqash, Abdul Rafeh, Arjun Mittra, Geraldine O’Sullivan Coyne, et al.. (2020). Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).. Journal of Clinical Oncology. 38(15_suppl). 3624–3624. 3 indexed citations

Coyne, Geraldine O’Sullivan, Richard Piekarz, Naoko Takebe, et al.. (2019). Trial in progress abstract phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). TPS3148–TPS3148. 1 indexed citations

Mittra, Arjun, Geraldine O’Sullivan Coyne, Sarina A. Piha‐Paul, et al.. (2019). Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3067–3067. 8 indexed citations

Coyne, Geraldine O’Sullivan, Kevin C. Conlon, Naoko Takebe, et al.. (2018). Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers.. Journal of Clinical Oncology. 36(15_suppl). TPS3128–TPS3128. 2 indexed citations

Takebe, Naoko, Geraldine O’Sullivan Coyne, Shivaani Kummar, et al.. (2018). Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775.. Journal of Clinical Oncology. 36(15_suppl). 2587–2587. 4 indexed citations

Coyne, Geraldine O’Sullivan, Shivaani Kummar, Naoko Takebe, et al.. (2018). Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 2549–2549. 11 indexed citations

10.

Teply, Benjamin A., Hao Wang, Brandon Luber, et al.. (2017). Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. The Lancet Oncology. 19(1). 76–86. 137 indexed citations

11.

Teply, Benjamin A., Hao Wang, Rana Sullivan, et al.. (2017). Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza).. Journal of Clinical Oncology. 35(15_suppl). 5017–5017. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact